Evidence map›Paper›PMID 29663436›Full record

ArticleClinical cardiology2018

Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.

Julio Núñez, Patricia Palau, Eloy Domínguez, Anna Mollar, Eduardo Núñez, Jose María Ramón, Gema Miñana, Enrique Santas, Lorenzo Fácila, Jose Luis Górriz and 2 more

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07482943 phase4recruitingstarted 2026, after this paper: background citation

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Ran2026Enrolled30Registered outcomes13Posted comparisons0ConditionsCardiovascular Diseases, Dapagliflozin, Fontan, Heart FailureArmsDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
PMID 33736819PMID 34447992PMID 34900549PMID 34936056PMID 35379503PMID 35948644PMID 36530388PMID 37615988PMID 31535829PMID 11889012PMID 17543747PMID 19915891other papers from this trial
Open the trial in the graph
NCT04197635 phase4completednot on this mapstarted 2019, after this paper: background citation

Short-term Effects of Dapagliflozin on Peak VO2 in Patients With Heart Failure With Reduced Ejection Fraction

TypeinterventionalSponsorFundación para la Investigación del Hospital Clínico de ValenciaRan2019 to 2022Enrolled74ConditionsHeart Failure With Reduced Ejection FractionArmsMaximal functional capacity by cardiopulmonary exercise testing, Echocardiography, Evaluation of health related quality of life, Submáximal functional capacity assesment by 6 minutes walk test, Clinical evaluation
NCT06668389 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial (STEPS Trial)

TypeinterventionalSponsorThe University of Hong KongRan2025 to 2026Enrolled106ConditionsCongenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation, Sodium-glucose Cotransporter 2 (SGLT2) InhibitorArmsSGLT2 inhibitor (Dapagliflozin 10mg)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julio NúñezCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.ORCID http://orcid.org/0000-0003-1672-7119
Patricia PalauCardiology Department, Hospital General Universitario de Castellón, Universitat Jaume I, Castellón, Spain.
Eloy DomínguezCardiology Department, Hospital General Universitario de Castellón, Universitat Jaume I, Castellón, Spain.
Anna MollarCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Eduardo NúñezCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Jose María RamónCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Gema MiñanaCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.ORCID http://orcid.org/0000-0001-8777-2588
Enrique SantasCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Lorenzo FácilaCardiology Department, Hospital General Universitario de Valencia, Valencia, Spain.
Jose Luis GórrizNephrology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Juan SanchisCardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
Antoni Bayés-GenísCIBER Cardiovascular, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HYPOTHESIS: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF.

methodsNineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used.

resultsMedian patient age was 72 years (interquartile range, 60-79 years); 42.1% were in New York Heart Association class III. Baseline mean (± SD) peak oxygen consumption (peak VO

conclusionsIn this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.

Indexed as

AgedBenzhydryl CompoundsDiabetes Mellitus, Type 2Exercise ToleranceFemaleGlucosidesHeart FailureHumansHypoglycemic AgentsMaleMiddle AgedOxygen ConsumptionPilot ProjectsProspective StudiesPulmonary VentilationQuality of LifeBenzhydryl CompoundsempagliflozinGlucosidesHypoglycemic AgentsEmpagliflozinExercise CapacityHeart Failure

Identifiers

PMID29663436
PMCPMC6489772

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.